No Proof Of Added Benefit For Perampanel In Epilepsy
Tuesday, August 19, 2014 - 19:40
in Health & Medicine
The drug perampanel (trade name Fycompa) has been approved since July of 2012 as an adjunctive ("add-on") therapy for adults and children aged 12 years and older with seizures - colloquially also known as epileptic fits. In a new early benefit assessment, according to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether perampanel offers an added benefit over the appropriate comparator therapy. read more